Skip to site menu Skip to page content

Granata Bio concludes screening in Phase III GRACE trial for IVF

The randomised, multi-centre, placebo-controlled, double-blind trial screened over 750 women across fertility clinics in the US.

Salong Debbarma October 23 2026

Granata Bio has completed participant screening in its Phase III GRACE trial of Granata Bio human menopausal gonadotropin (GB-hMG) in women who are undergoing in vitro fertilisation (IVF).

The biopharmaceutical developer expects data from the study to support a potential biologics licence application (BLA) for GB-hMG.

The randomised, multi-centre, placebo-controlled, double-blind trial screened over 750 women across fertility clinics in the US. Granata Bio expects to enrol around 625 participants aged between 18 and 42 years across two cohorts.

With screening concluded, the clinical programme is advancing through active treatment, embryo transfer, and pregnancy follow-up, with the first live birth anticipated by the end of this year.

Granata Bio CEO Evan Sussman said: “15 exceptional fertility clinics chose to participate in GRACE, and their investigators and study teams have done a tremendous job identifying, screening and enrolling these cohorts.

“We're grateful to everyone who considered participating in GRACE, and we hope that those who enrolled have great outcomes, both in the study and in building their families.”

Granata Bio scientific affairs head Barbara Cometti said: “GRACE is designed to evaluate the cumulative live birth rate following a single stimulation cycle with Granata's GB-hMG.

“This means following participants throughout their entire treatment journey, from ovarian stimulation through all available embryo transfers.

“While this approach requires time, it allows us to assess the outcome that ultimately matters most: the chance of achieving a live birth.”

The GRACE study is designed to assess the safety and efficacy of GB-hMG in developing multiple follicles, achieving pregnancy, and supporting cumulative live births during an assisted reproductive technology (ART) cycle.

Enrolled subjects will proceed through planned treatment and follow-up periods, with Granata Bio intending to provide further updates as the research continues.

Founded in 2018, Granata Bio is a biopharmaceutical company focused on reproductive health. The business develops and accelerates fertility therapies intended to broaden treatment options, expand access, and improve affordability.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close